COLL Stock Overview
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.
No risks detected for COLL from our risk checks.
Notes are coming soon
Collegium Pharmaceutical, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$28.29|
|52 Week High||US$30.22|
|52 Week Low||US$14.04|
|1 Month Change||21.94%|
|3 Month Change||57.69%|
|1 Year Change||61.84%|
|3 Year Change||40.64%|
|5 Year Change||25.18%|
|Change since IPO||130.19%|
Recent News & Updates
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?Oct 18
Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance SheetJun 24
There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is UndemandingFeb 15
We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its DebtOct 30
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Is Looking A Bit Stretched At The MomentMay 14
Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) EarningsMay 13
We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its DebtMay 01
Read This Before Judging Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROEFeb 20
Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance SheetJan 16
Collegium Pharmaceutical (NASDAQ:COLL) Share Prices Have Dropped 27% In The Last Five YearsDec 12
|COLL||US Pharmaceuticals||US Market|
Return vs Industry: COLL exceeded the US Pharmaceuticals industry which returned 4.5% over the past year.
Return vs Market: COLL exceeded the US Market which returned -9.2% over the past year.
|COLL Average Weekly Movement||6.8%|
|Pharmaceuticals Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: COLL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: COLL's weekly volatility (7%) has been stable over the past year.
About the Company
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. Fundamentals Summary
|COLL fundamental statistics|
Is COLL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|COLL income statement (TTM)|
|Cost of Revenue||US$68.78m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.28|
|Net Profit Margin||-11.84%|
How did COLL perform over the long term?See historical performance and comparison